Senhwa Biosciences, Inc. (TPEX:6492)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
38.95
+0.15 (0.39%)
Apr 2, 2025, 1:30 PM CST
-11.88%
Market Cap 3.46B
Revenue (ttm) 1.00M
Net Income (ttm) -293.75M
Shares Out 89.19M
EPS (ttm) -3.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 74,166
Average Volume 161,627
Open 38.55
Previous Close 38.80
Day's Range 38.50 - 39.25
52-Week Range 37.60 - 64.50
Beta 1.03
RSI 26.50
Earnings Date Mar 13, 2025

About Senhwa Biosciences

Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidna... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6492
Full Company Profile

Financial Performance

In 2024, Senhwa Biosciences's revenue was 1.00 million, a change of 0.00% compared to the previous year's 1.00 million. Losses were -293.75 million, -0.86% less than in 2023.

Financial Statements

News

There is no news available yet.